Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio
Key Highlights
- ➤Q3 revenue $24.4 billion, up 39%, driven primarily by Mounjaro and Zepbound
- ➤Mounjaro revenue $10.7 billion, up 65%, led by strong global volume growth
- ➤Zepbound U.S. revenue $5.3 billion, up 48%, driven primarily by strong demand
- ➤2026 revenue guidance raised to $91.0-$92.0 billion from $85-$87 billion
- ➤2026 non-GAAP EPS guidance reduced to $35.00-$36.00 after $4.57 acquired IPR&D charges
Expert Statements
David A. Ricks, Chair and CEO of Lilly
“Lilly had another strong quarter, exceeding our prior expectations and allowing us to raise our full-year outlook”
David A. Ricks, Chair and CEO of Lilly
“Revenue growth was driven by broad global consumer demand for Mounjaro and Zepbound, the global launches of Foundayo, expanded U.S. coverage for obesity care and a doubling in our newest products in oncology, immunology and neuroscience.”
David A. Ricks, Chair and CEO of Lilly
“To drive durable long-term growth, we continue to invest in our drug-making and technology capabilities, with multiple business development deals and partnerships signed and closed, and with new manufacturing expansions in Texas and Virginia.”
David A. Ricks, Chair and CEO of Lilly
“Lilly is executing well across the value chain, and our potential for impact on human health continues to expand.”
Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio PR Newswire
* Revenue in Q3 2026 increased 39% to $24.4 billion driven primarily by Mounjaro and Zepbound. * Q3 revenue included approximately $900 million of benefits, primarily from $410 million of Jardiance milestones (no further milestones remain) and favorable adjustments to rebate and discount estimates. * Q3 2026 EPS increased by 16% to $7.22 on a reported basis and increased by 7% to $7.48 on a non-GAAP basis. Q3 2026 reported and non-GAAP EPS included $4.57 of acquired IPR&D charges compared to $0.71 in Q3 2025. * Increased the midpoint of our 2026 full-year revenue guidance by $5.5 billion to be in the range of $91.0 to $92.0 billion and raised underlying non-GAAP EPS guidance for the full year by $4.07 at the midpoint, which was more than offset by $4.57 of acquired IPR&D charges from Q3 business development activity, resulting in an updated range of $35.00 to $36.00. * Regulatory progress included U.S. FDA approvals of Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes; Onswik, a once-weekly basal insulin for adults with type 2 diabetes; Inluriyo with Verzenio for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer; and an expanded indication for Jaypirca in adults with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. * Pipeline highlights included positive topline results from a head-to-head Phase 3 trial of retatrutide versus Ozempic 2 mg in adults with type 2 diabetes, Phase 3 results from Ebglyss in moderate-to-severe hand and foot atopic dermatitis and Phase 2 results from EloraTZP in adults with obesity and type 2 diabetes, with Phase 3 trials to start in Q4 2026. * Business development activity in Q3 2026 included the completed acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions. Subsequent to quarter end, we completed the acquisition of Merida Biosciences, to advance treatments for serious autoimmune and allergic diseases. INDIANAPOLIS, Oct. 29, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the third quarter of 2026 and provided updated 2026 financial guidance.
Get started
Create a free account to read the full story.